The new rule imposes a 10% fee-for-service cut on any provider who doesn’t opt into a managed-care network, and rural hospitals are especially concerned about the financial losses the change may cause.
On July 1, Missouri transferred state-run health coverage for approximately 240,000 low-income adults and children to managed care plans run by 3 companies (Centene, UnitedHealthcare, and WellCare) as part of its privatization of Missouri’s Medicaid program.
The new rule imposes a 10% fee-for-service (FFS) cut on any provider who doesn’t opt into a managed-care network. Rural hospitals are especially concerned about the financial losses the change may cause.
According to the Missouri Hospitals Association (MHA), all hospitals in the state have contracts with at least 1 of the 3 managed care companies and all but 12 have a contract with all 3 companies. Truman Medical Center is one of the 12, and its CFO Allen Johnson said the organization could not absorb the 10% reduction. “Financially I think this will be a disaster for Truman,” Johnson said, noting that it is the county’s safety net hospital and 55% of its revenue comes from Medicaid.
The intent of the state’s change is to increase provider participation in managed care plans. Critics of the change say the transfer puts patient health at risk. Some providers have warned that it will discourage private practices from accepting Medicaid, which is typically reimbursed at low rates, and will reduce access to physicians who are currently willing to care for the Medicaid population, forcing more Medicaid patients to turn to emergency departments. State Senator Rob Schaaf, a family practice physician, warned, “Managed care companies’ jobs is to ration care, to keep people from getting the care that they need, and they make money doing that.”
Insurance companies counter that they save money by keeping patients healthy and can pass on those savings to the state and thus have no incentive to deny needed care. Payment rates were higher in Missouri than for similar business in other states, according to one insurer, and lowering the rates will mean cost savings for the state.
Providers fear there is no incentive for insurers to negotiate with them if the state has “tipped the scales” in favor of insurers, giving them greater bargaining power. MHA CEO Herb Kuhn pointed out that if a hospital doesn’t agree to accept whatever payment rate the Medicaid managed care plan offers, the plan can simply refuse to sign a contract, locking in the FFS level cut. Capital Region Medical Center in Jefferson City reported that one of the 3 managed care plans terminated its contract with his hospital without even attempting to negotiate, and other hospital leaders have reported similar plan terminations by insurance companies.
The managed care companies get a flat fee from the state to cover each patient through Medicaid and then pay the clinic directly for care. Previously the state paid the clinic directly (which is still in effect for seniors and people with disabilities). Providers note that contracts must now be negotiated with each managed care plan instead of payments being determined by the state, and they are concerned that managed care plans might require a patient to contact their insurer to preauthorize higher-level care.
While Medicaid’s transition into managed care is gaining ground across the country, some states, particularly rural ones, have had problems with the transition, especially if they did not expand Medicaid. For example, Iowa, which moved to managed care for Medicaid and underestimated the per-person cost, had to seek hundreds of millions in federal dollars to cover the costs of its program and keep the plans in contract.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.